GlassScriptPhysician profile
Monique Y Brown
NPI 1336289636
$9,758.33
in general payments reported to CMS, 2019-2025
33 companies · $2,007 in 2025
The $2,007 reported for 2025 was more than what 96% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,927 · 2020: $625 · 2021: $1,375 · 2022: $1,601 · 2023: $1,036 · 2024: $1,188 · 2025: $2,007.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,231.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,172.68 | 2019-2025 | Uzedy, Austedo, Austedo Xr |
| Abbvie INC. | $1,019.22 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Alkermes, INC. | $962.32 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $871.65 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $724.29 | 2019-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $597.89 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $512.66 | 2019-2024 | Jornay Pm |
| Allergan, INC. | $456.83 | 2019-2020 | |
| Tris Pharma INC | $412.39 | 2019-2025 | Dyanavel Xr |
| Corium, LLC | $378.49 | 2021-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $343.96 | 2021-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $250.67 | 2019-2024 | Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $235.02 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $232.29 | 2024-2025 | Auvelity, Symbravo |
| E.R. Squibb & Sons, L.L.C. | $224.77 | 2024-2025 | Cobenfy |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $187.60 | 2024 | Farxiga |
| Vanda Pharmaceuticals INC. | $171.12 | 2021-2025 | Fanapt, Hetlioz |
| Idorsia Pharmaceuticals US INC | $125.00 | 2023 | Quviviq |
| Adlon Therapeutics L.P. | $121.92 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $97.42 | 2019-2024 | Relexxii |
| Lundbeck LLC | $91.19 | 2022-2025 | Rexulti |
| Neos Therapeutics, LP | $85.93 | 2019-2023 | Cotempla Xr-Odt |
| Novo Nordisk INC | $74.80 | 2019-2025 | Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $69.35 | 2020-2022 | |
| Rhodes Pharmaceuticals L.P. | $61.37 | 2019 | |
| Shire North American Group INC | $60.54 | 2019 | |
| Pfizer INC. | $53.58 | 2025 | |
| Collegium Pharmaceutical, INC. | $47.25 | 2025 | Jornay Pm |
| Lilly USA, LLC | $43.20 | 2025 | Zepbound, Mounjaro |
| Ardelyx, INC. | $21.48 | 2025 | Ibsrela |
| Almatica Pharma LLC | $18.54 | 2022 | |
| Jazz Pharmaceuticals INC. | $16.75 | 2021 | |
| Arbor Pharmaceuticals, INC. | $16.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monique Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.